These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 19527632

  • 1. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
    Grépin R, Pagès G.
    J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
    [Abstract] [Full Text] [Related]

  • 2. Vascular endothelial growth factor receptors: expression and function in solid tumors.
    Wey JS, Stoeltzing O, Ellis LM.
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
    Cao Y, Liu Q.
    Adv Cancer Res; 2007 Jan; 97():203-24. PubMed ID: 17419947
    [Abstract] [Full Text] [Related]

  • 4. Current overview of angiogenesis inhibitors.
    Ellis LM.
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract] [Full Text] [Related]

  • 5. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
    Coltrini D, Ronca R, Belleri M, Zardi L, Indraccolo S, Scarlato V, Giavazzi R, Presta M.
    J Pathol; 2009 Dec; 219(4):455-62. PubMed ID: 19824060
    [Abstract] [Full Text] [Related]

  • 6. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
    Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G.
    Cancer Res; 2003 Jun 15; 63(12):3403-12. PubMed ID: 12810677
    [Abstract] [Full Text] [Related]

  • 7. [Inhibition of angiogenesis by proteins, peptides and "small molecules"].
    Jayson G, Armand JP, Berdel WE.
    Onkologie; 2005 Oct 15; 28 Suppl 4():29-34. PubMed ID: 16205103
    [No Abstract] [Full Text] [Related]

  • 8. [Tumour angiogenesis inhibition by therapeutic monoclonal antibodies].
    Cézé N, Lecomte T, Watier H.
    Med Sci (Paris); 2009 Dec 15; 25(12):1099-104. PubMed ID: 20035685
    [Abstract] [Full Text] [Related]

  • 9. [VEGF, anti-vEGF and diseases].
    Corvol P.
    Bull Acad Natl Med; 2008 Feb 15; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
    [Abstract] [Full Text] [Related]

  • 10. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.
    Larcher F, Robles AI, Duran H, Murillas R, Quintanilla M, Cano A, Conti CJ, Jorcano JL.
    Cancer Res; 1996 Dec 01; 56(23):5391-6. PubMed ID: 8968091
    [Abstract] [Full Text] [Related]

  • 11. [VEGF and its receptors as therapeutic target in cancer therapy].
    Gisterek I, Kornafel J.
    Przegl Lek; 2006 Dec 01; 63(3):155-7. PubMed ID: 16967703
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic anti-VEGF antibodies.
    Lien S, Lowman HB.
    Handb Exp Pharmacol; 2008 Dec 01; (181):131-50. PubMed ID: 18071944
    [Abstract] [Full Text] [Related]

  • 13. Breast tumour angiogenesis.
    Fox SB, Generali DG, Harris AL.
    Breast Cancer Res; 2007 Dec 01; 9(6):216. PubMed ID: 18190723
    [Abstract] [Full Text] [Related]

  • 14. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G.
    Cancer Res; 2015 Oct 01; 75(19):4086-96. PubMed ID: 26377940
    [Abstract] [Full Text] [Related]

  • 15. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
    Eskens FA, Verweij J.
    Eur J Cancer; 2006 Dec 01; 42(18):3127-39. PubMed ID: 17098419
    [Abstract] [Full Text] [Related]

  • 16. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ, Ellis LM.
    J Clin Oncol; 2005 Feb 10; 23(5):1011-27. PubMed ID: 15585754
    [Abstract] [Full Text] [Related]

  • 17. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR, Sunila ES, Kuttan G.
    Integr Cancer Ther; 2005 Dec 10; 4(4):315-21. PubMed ID: 16282508
    [Abstract] [Full Text] [Related]

  • 18. Angiogenesis inhibitors in the treatment of lung cancer.
    Sun S, Schiller JH.
    Crit Rev Oncol Hematol; 2007 May 10; 62(2):93-104. PubMed ID: 17306557
    [Abstract] [Full Text] [Related]

  • 19. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
    van Kempen LC, Leenders WP.
    Eur J Cell Biol; 2006 Feb 10; 85(2):61-8. PubMed ID: 16439306
    [Abstract] [Full Text] [Related]

  • 20. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR.
    Cancer Res; 1999 Jul 15; 59(14):3374-8. PubMed ID: 10416597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.